US Patent

US7781577 — Inhibitors of sodium glucose co-transporter 2 and methods of their use

Method of Use · Assigned to Lexicon Pharmaceuticals Inc · Expires 2028-05-04 · 2y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.

USPTO Abstract

Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3628 — Inpefa
U-3628 — Inpefa

Patent Metadata

Patent number
US7781577
Jurisdiction
US
Classification
Method of Use
Expires
2028-05-04
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Lexicon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.